Follow-up: Inovio 18.9M share Spot Secondary priced at $2.90 The deal range was raised to 18.9M shares from 13.4M shares. Piper Jaffray and Stifel acted as joint book running managers for the offering.
News For INO From The Last 14 Days
Check below for free stories on INO the last two weeks.
Inovio's VGX-3100 for cervical dysplasia shows positive Phase II results Inovio Pharmaceuticals announced successful results from its randomized, double-blind, placebo-controlled phase II trial of VGX-3100 in women with biopsy-proven cervical intraepithelial neoplasia 2/3 associated with human papillomavirus types 16 or 18. Treatment with VGX-3100 resulted in histopathological regression of CIN2/3 to CIN1 or no disease, meeting the study's primary endpoint. The trial demonstrated clearance of HPV in conjunction with regression of cervical lesions. Robust T-cell activity was detected in subjects who received VGX-3100 compared to those who received placebo.